Alon Natanson New BrainStorm CEO

BrainStorm Cell Therapeutics (OTC.QB: BCLI), has appointed Alon Natanson as its new Chief Executive Officer (CEO). Natanson succeeds Dr. Adrian Harel, who will move into an executive scientific role in the company. Prior to joining BrainStorm, Natanson, 49, led large as well as early-stage companies in the fields of life science, high-tech, and retail. Previously, as Director of Marketing and Finance in Teva Pharmaceuticals’ (NYSE:TEVA) Copaxone division, he played a key role in the commercialization of patented therapeutics for multiple sclerosis, establishing the division and executing its international strategy and product launch. Mr. Natanson has also led the successful turnaround of two insolvent American retail companies, transforming them into growing organizations with substantial gross margins. Since 2008, he served as President and CEO of Procognia (TASE: PRCG), a biotechnology company specializing in glycobiology and biopharmaceutical analytics.

Written by

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam libero diam, elementum eget porttitor at, tincidunt at nulla.